| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BriaCell Therapeutics Corp. Warrant expiring 2031$0.8
0 (0%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
62.31 K
SEC Financials
Q2 2026Dilution Risk
R&D Expenses
5.97 M
Total Assets
27.07 M
Total Liabilities
27.07 M
Equity
23.41 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
22.80 M
Monthly Burn
2.54 M
Runway
8.7 mo
Burn Trend
StableSEC Filing
Jun 9, 2026
Overview
Volume
15.05 K
52 Week Range
-
% held by Insiders
-
% held by Institutions
-
Enterprise Value
-
Total Shares
-
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCTXL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BCTXL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BCTXL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BCTXL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BCTXL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BCTXL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BCTXL
May 31, 2026BriaCell Therapeutics Announces Pricing of Offering Philadelphia & Vancouver, British Columbia
BriaCell Therapeutics Corp. has announced the pricing of an offering for 1,449,300 common shares at $3.25 each, aiming to raise about $4.7 million in gross proceeds. The offering is set to close on June 2, 2026, subject to customary closing conditions. The company plans to utilize the net proceeds for working capital and general corporate purposes, alongside advancing its business objectives. The offering is offered under a shelf registration statement filed with the SEC.
Read more →-BCTXL
Mar 31, 2026BRIAPRO THERAPEUTICS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2026 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompa
BriaPro Therapeutics Corp. has released its interim financial statements for the three and six-month periods ending January 31, 2026. The company recorded a total operating loss of $497,943 for the first half of the fiscal year and has accumulated a significant deficit since its inception. Additionally, the financial statements highlight the company's reliance on external financing to continue its operations, as it has yet to enter commercial operations. The ability of BriaPro to continue as a going concern is in doubt, as it requires future capital to sustain its research and development activities.
Read more →-BCTXL
Feb 18, 2026BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. and its subsidiary BriaPro have entered into a definitive asset purchase agreement granting BriaPro exclusive rights to develop and commercialize Soluble CD80 for cancer treatment. This novel immunotherapy, backed by promising animal model data, aims to revive immune responses against tumors. In exchange for the license, BriaPro will issue shares to BriaCell, increasing its ownership post-transaction. The deal is expected to finalize around March 12, 2026, pending necessary approvals and conditions.
Read more →-BCTXL
Jan 13, 2026BriaCell Therapeutics Announces Pricing of $30 million Public Offering Philadelphia & Vancouver, British Columbia
BriaCell Therapeutics Corp. has announced a public offering priced at $5.59 per unit, targeting gross proceeds of approximately $30 million. Each unit includes a common share and a warrant, which will be traded on the Nasdaq under the symbol 'BCTXL'. The company plans to utilize the proceeds for working capital and to further its business objectives. The offering is expected to close on January 15, 2026, pending customary closing conditions. This announcement follows the effective registration statement with the SEC.
Read more →-BCTXL
Dec 29, 2025BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanying Unau
BriaPro Therapeutics Corp. released its unaudited condensed interim consolidated financial statements for the three months ending October 31, 2025. The report shows a net loss of $244,738, with an accumulated deficit of $1,425,163 since the company's incorporation. The financial statements indicate that the company is in the pre-clinical research stage and has not started commercial operations. There are significant concerns about the company's ability to continue as a going concern without additional financing, highlighting a reliance on its holding company, BriaCell Therapeutics Corp.
Read more →-BCTXL
Dec 1, 2025BRIAPRO THERAPEUTIC CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2025 (Expressed in United States Dollars) Independent Auditor's Report To the Shareholders of BriaPro Therapeutics Corp.: Opinion
BriaPro Therapeutics Corp. announced its consolidated financial statements for the period ending July 31, 2025, as audited by MNP LLP. The report indicates a fair presentation of the company's financial position but highlights significant losses incurred since incorporation. It notes that the company remains in pre-clinical research and has not started commercial operations. Additionally, the auditors draw attention to uncertainties surrounding the company's ability to continue as a going concern due to ongoing financial losses.
Read more →-BCTXL
Aug 21, 2025BriaCell Announces Proposed Effective Date of Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced a proposed share consolidation, with an effective date set for August 25, 2025. The consolidation will adjust the company's outstanding common shares on a ratio of one post-consolidation share for every ten pre-consolidation shares. This move is aimed at ensuring compliance with the Nasdaq listing requirements and is pending approval from both Nasdaq and the Toronto Stock Exchange. Shareholders will receive instructions regarding the exchange of their shares after the effective date.
Read more →-BCTXL
Jul 15, 2025BriaCell Therapeutics Announces Pricing of $15 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced the pricing of a public offering aimed at raising $15 million through the sale of 12 million units, each priced at $1.25. The offering includes common shares and warrants, with the exercise price of the warrants set at $1.50 per share. The proceeds from this offering are intended to support working capital needs and further the company's objectives in the field of immunotherapies for cancer care. Expected closure of the offering is scheduled for July 16, 2025, pending customary conditions.
Read more →-BCTXL
Jun 18, 2025BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanyi
BriaPro Therapeutics Corp. released its unaudited condensed interim consolidated financial statements for the periods ending April 30, 2025. The report highlights an increased accumulated deficit and substantial operating losses, which raised concerns about the company's financial health. Current liabilities saw a considerable increase, further stressing the firm's precarious position. The company, focused on immuno-oncology, is experiencing growing operational expenses, notably in research and development.
Read more →-BCTXL
Apr 24, 2025BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics has announced the pricing for its public offering, raising approximately $13.8 million with the sale of 3,066,666 units. Each unit consists of one common share and one warrant, with pricing set at $4.50 per unit. The warrants will be listed on Nasdaq under the symbol 'BCTXZ' and are immediately exercisable at a price of $5.25 per share. The transaction is anticipated to close on April 28, 2025, contingent upon customary conditions.
Read more →-BCTXL
Mar 12, 2025BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompany
BriaPro Therapeutics Corp. has released its interim consolidated financial statements for the periods ended January 31, 2025, revealing a deteriorating financial position. The company reported a significant operating loss of $151,062 for the quarter, alongside a total shareholders' deficit of $638,879. Operating expenses continue to rise, while cash reserves remain stagnant at just $1. The lack of an independent auditor's review also raises concerns about the credibility of the financial reports.
Read more →-BCTXL
Feb 3, 2025BriaCell Therapeutics Announces Proposed Public Offering of Common Shares PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics has announced a proposed public offering of common shares to support its business objectives and working capital. The offering's success is subject to market conditions and does not guarantee a specific size or terms. The company relies on the exemption for eligible interlisted issuers and has filed a related prospectus with the SEC. The announcement underscores the ongoing efforts of BriaCell to fund its immunotherapy developments amid inherent uncertainties.
Read more →-BCTXL
Jan 27, 2025BriaCell Announces Completion of 15:1 Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has completed a 15:1 share consolidation to ensure compliance with Nasdaq listing requirements. This consolidation reduces the total number of outstanding shares from over 44 million to approximately 2.9 million. The newly consolidated shares are expected to start trading on the TSX and Nasdaq on January 29, 2025. Shareholders are advised on the necessary steps to convert their physical share certificates and ensure they receive the new shares, while some risks and uncertainties remain associated with future trading activities.
Read more →-BCTXL
Jan 3, 2025BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to
BriaCell Therapeutics Corp. has announced the rescheduling of its Annual General Meeting of Shareholders to February 5, 2025, due to disruptions in postal service. The record date remains unchanged as December 9, 2024. Shareholders who have previously voted do not need to take any action unless they wish to change their votes. The meeting will cover essential topics, including the election of directors and the appointment of auditors.
Read more →-BCTXL
Dec 16, 2024BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2024 (Unaudited) (Expressed in United States Dollars) F- 1 BriaPro Therapeutics Corp. Unaudited Co
BriaPro Therapeutics Corp. released its interim consolidated financial statements for the three-month period ending October 31, 2024. The company reported an operating loss of $82,123, which, despite being an improvement from the previous year, highlights ongoing financial struggles. The total shareholders' deficit has increased to $487,817, and the company continues to operate with only $1 in cash. Additionally, the rise in current liabilities to $522,835 raises concerns about its financial stability and ability to sustain operations.
Read more →-BCTXL
Dec 11, 2024BriaCell Therapeutics Announces Proposed Public Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics announced its intention to conduct an underwritten public offering of common shares and warrants. The company plans to utilize the proceeds primarily for working capital and advancing corporate objectives. Terms of the offering remain subject to market conditions and may not be guaranteed. Forward-looking statements within the release highlight various uncertainties and risks associated with the offering.
Read more →-BCTXL
Nov 1, 2024BRIAPRO THERAPEUTIC CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2024 (Expressed in United States Dollars) Independent Auditor's Report To the Shareholders of BriaPro Therapeutics Corp.: Opinion
BriaPro Therapeutics Corp. has released its consolidated financial statements for the period ending July 31, 2024. An independent auditor's report indicated that the financial statements fairly represent the company's position but emphasized a concern regarding its ability to continue as a going concern due to net losses since incorporation. The company is still in the pre-clinical research stage, which may lead to ongoing financial challenges and uncertainties.
Read more →-BCTXL
Oct 1, 2024BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced a $5 million offering priced at-the-market under Nasdaq rules, intending to issue 5,128,500 common shares and warrants. The offering is expected to close on October 2, 2024, and the proceeds will be used for working capital and corporate purposes. As part of the offering process, the company will file relevant documentation with the SEC. However, there are inherent risks associated with forward-looking statements regarding the offering's completion.
Read more →-BCTXL
Oct 1, 2024BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with "Ey
BriaCell Therapeutics Corp. reported a groundbreaking case of a patient with metastatic breast cancer experiencing a 100% resolution of a brain metastasis following treatment with the Bria-IMT regimen combined with an immune checkpoint inhibitor. The patient had previously failed eight treatments but has now completed a year of therapy showing significant tumor reduction. Along with the resolution of brain lesions, there has been a marked decrease in tumor markers. These findings suggest that the Bria-IMT regimen could provide a new therapeutic option for patients with brain metastases from metastatic breast cancer.
Read more →-BCTXL
Sep 11, 2024BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced a $8.5 million offering of common shares under Nasdaq rules, expected to close on September 12, 2024. The company is pricing 12,325,000 shares at $0.69 each, with proceeds intended for working capital and business advancement. This offering highlights BriaCell's ongoing development in novel immunotherapies for cancer care, although there are inherent risks and uncertainties related to the offering's completion and forward-looking projections.
Read more →-BCTXL
Sep 9, 2024BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. announced that it will present a poster at the 2024 Society for Immunotherapy of Cancer Annual Meeting in Houston, Texas, scheduled for November 6-10, 2024. The poster presentation will focus on the company's advancements in novel immunotherapies aimed at improving cancer care, particularly for breast and prostate cancer patients. The announcement highlights BriaCell's commitment to its clinical research and the significant opportunities ahead in cancer treatment innovations.
Read more →-BCTXL
Jul 18, 2024BriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast Cancer Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients i
BriaCell Therapeutics Corp. announced significant results from its Phase 2 study of the Bria-IMT regimen for treating metastatic breast cancer. A heavily pre-treated patient achieved a progression-free survival (PFS) of 9.1 months, which is four times longer than reported in similar cases. The patient's tumors have markedly shrunk, and she continues to benefit from the treatment. BriaCell's leadership expressed optimism about replicating these results in an ongoing Phase 3 study aimed at addressing unmet medical needs for cancer patients.
Read more →-BCTXL
Jun 14, 2024BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTER
BriaPro Therapeutics Corp. has released its interim financial statements for the three and nine month periods ending April 30, 2024, which were not reviewed by an auditor. The financial results reflect significant losses totaling $366,960, and the company shows an accumulated deficit of $336,439 since its incorporation. The firm is currently in the pre-clinical research stage and has yet to commence commercial operations. Despite acquiring assets from Briacell Therapeutics Corp., BriaPro's liquidity and operational status raise concerns regarding its future viability.
Read more →-BCTXL
May 15, 2024BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced the pricing of a $5.0 million registered direct offering of common shares and warrants. The offering involves securities purchase agreements with institutional investors and existing stakeholders. The gross proceeds will primarily support working capital and research, particularly a pivotal Phase 3 study in advanced breast cancer. The offering is expected to close on May 17, 2024, subject to customary conditions.
Read more →-BCTXL
Apr 2, 2024BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTE
BriaPro Therapeutics Corp. released its unaudited interim financial statements for the three and six months ending January 31, 2024. The statements indicate the company has incurred considerable losses amounting to $257,057 over six months and $125,294 over three months, alongside an accumulated deficit of $265,882. Overall, the financial position reflects liabilities that significantly outpace current assets, raising concerns about the company's financial health.
Read more →-BCTXL
Dec 20, 2023BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS
BriaCell Therapeutics Corp. reports promising preliminary data showing significant survival benefits in advanced breast cancer patients who are resistant to antibody-drug conjugates (ADCs). In a subset analysis involving 23 patients, the company observed that the overall survival rates exceeded those reported in similar studies. Furthermore, 40% of patients experienced a disease control rate and similar or better progression-free survival compared to their previous treatments. Importantly, treatment with the Bria-IMT regimen showed no significant toxicity issues, including no cases of Interstitial Lung Disease.
Read more →-BCTXL
Dec 14, 2023BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 (Unaudited) (Expressed in United States Dollars) F- 1 BriaPro Therapeutics Corp. Unaudited Condensed Inter
BriaPro Therapeutics Corp. issued its unaudited interim financial statements for the three months ending October 31, 2023. The company reported total assets of $211,251, primarily consisting of intangible assets valued at $211,250. However, it recorded a substantial operating loss of $128,026 during this period. The financial statements emphasize the company's current inactivity in commercial operations, as it is still in the research phase and must secure additional funding to support its future endeavors.
Read more →-BCTXL
Nov 30, 2023BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor After only 3 cycles, patient experienced a remarkable improvement of eye-bulging "proptosis" caused by orbital metastatic breas
BriaCell Therapeutics Corp. reported a remarkable response in a heavily treated patient with metastatic breast cancer who experienced significant improvement in proptosis and reduction in ocular pain after just three cycles of their Bria-IMT treatment. The patient, who had previously undergone seven different treatments without success, continues to receive the regimen which has been well-tolerated. Additional clinical data related to this Phase 2 study will be presented at the upcoming San Antonio Breast Cancer Symposium.
Read more →-BCTXL
Nov 3, 2023BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND BriaCell dem
BriaCell Therapeutics has showcased remarkable anti-tumor efficacy of its next-generation personalized immunotherapies for breast and prostate cancer at the 2023 SITC Annual Meeting. The FDA has also approved the Investigational New Drug Application for Bria-OTS, allowing for clinical studies to commence. The findings indicate profound immune system activation mechanisms that may enhance treatment outcomes while maintaining patient safety. These developments signal a significant advancement in BriaCell's approach to cancer care, supporting the potential for broader applications across various cancer types.
Read more →-BCTXL
Oct 25, 2023BRIAPRO THERAPEUTIC CORP. FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 (Expressed in United States Dollars) F- 1 F- 2 F- 3 BriaPro Therapeutics Corp. Statement of Financial Position As at
BriaPro Therapeutics Corp. released its financial statements for the period ended July 31, 2023, indicating that the company is in its development stage. Although it was incorporated on May 15, 2023, it is currently inactive and has not yet started commercial operations. It holds multiple assets aimed at immuno-oncology but faces challenges in securing necessary financing. The company's continuation depends on its ability to achieve profitable operations and raise capital to support its ongoing development.
Read more →-BCTXL
Sep 8, 2023BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 m
BriaCell Therapeutics Corp. has reported promising results from its Phase 2 clinical study in advanced metastatic breast cancer, showing a median overall survival of 13.5 months, substantially surpassing the typical survival range of 6.7 to 9.8 months for similar patients. The treatment demonstrated no dose-limiting toxicities, with 21 out of 29 patients treated since 2022 still alive, suggesting significant clinical benefit. Leading researchers have highlighted the potential of BriaCell's combination regimen to improve outcomes for heavily pre-treated patients. Patient enrollment for the study is now complete, moving towards further pivotal studies to advance this promising treatment option.
Read more →-BCTXL
Aug 31, 2023BRIACELL THERAPEUTICS CORP. ANNOUNCES CLOSING OF PLAN OF ARRANGEMENT SPINNING OUT BRIAPRO THERAPEUTICS CORP. TO EXISTING SHAREHOLDERS BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in
BriaCell Therapeutics Corp. has successfully closed its plan of arrangement to spin out BriaPro Therapeutics Corp., transferring certain pipeline assets including Bria-TILsRx and protein kinase C delta inhibitors to the new subsidiary. Existing BriaCell shareholders will receive one common share of BriaPro for each share held, along with a new common share of BriaCell. The company remains publicly traded on NASDAQ and the Toronto Stock Exchange, with new BriaCell shares expected to begin trading on September 5, 2023.
Read more →-BCTXL
Aug 25, 2023BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders
BriaCell Therapeutics Corp. has received court approval for a plan to spin out its subsidiary, BriaPro Therapeutics, which will manage certain pipeline assets aimed at cancer treatment. Existing shareholders will receive one common share of the new entity for each share they hold in BriaCell, in addition to one new share of BriaCell. The spin-out is expected to occur around August 31, 2023, allowing BriaCell to remain publicly listed on NASDAQ and the Toronto Stock Exchange while SpinCo will operate as an unlisted reporting issuer in Canada.
Read more →-BCTXL
Aug 21, 2023BRIACELL THERAPEUTICS CORP. ANNOUNCES VOTING RESULTS FROM SPECIAL MEETING Shareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including Bria-TILsRx an
BriaCell Therapeutics Corp. announced that shareholders have approved the spinout of BriaPro Therapeutics, which will include key pipeline assets such as Bria-TILsRx and protein kinase C delta inhibitors for cancer treatment. The arrangement is expected to finalize around August 31, 2023, pending court and regulatory approvals. As part of the deal, shareholders will receive shares in both BriaCell and the new subsidiary, positioning BriaCell to focus on its core immunotherapy initiatives.
Read more →-BCTXL
Jun 27, 2023FDA Approves BriaCell's Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has received FDA approval for its pivotal registrational study design for Bria-IMT in combination with a checkpoint inhibitor targeting advanced metastatic breast cancer. This open-label study will focus on patients who have not responded to existing therapies and aims to assess the efficacy of this novel treatment. Successful results could lead to accelerated approval and significant advancements in treatment protocols for this challenging condition.
Read more →-BCTXL
May 25, 2023BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. announced a definitive arrangement agreement for the spin-out of its subsidiary, BriaPro Therapeutics Corp., which will handle specific pre-clinical immunotherapy assets. This strategic move is aimed at enhancing shareholder value and positioning the newly formed entity for greater success in developing cancer therapies. Shareholders will receive common shares in both companies following the completion of the arrangement. The spin-out is set to be approved at a special shareholder meeting in July 2023, pending various regulatory approvals.
Read more →-BCTXL
May 19, 2023BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share PHILADELPHIA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has completed a strategic investment of $4 million from Prevail Partners at a share price of $8.63. This investment, which aligns with the stock purchase agreement initiated on May 12, is intended to fund clinical services for upcoming studies focused on advanced metastatic breast cancer. The investment marks a significant endorsement of BriaCell's efforts to address cancer treatment challenges. Approval has been granted by the Toronto Stock Exchange, with customary post-close filings still required.
Read more →-BCTXL
May 15, 2023BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc. Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gro
BriaCell Therapeutics Corp. has announced a strategic investment worth $4 million from Prevail Partners, LLC, which will acquire 463,408 common shares at $8.63 each, reflecting a 20% premium. Additionally, Prevail InfoWorks, Inc. will act as the Contract Research Organization (CRO) for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer. The collaboration is expected to enhance clinical trial execution through real-time data analytics and extensive expertise, potentially facilitating expedited FDA approval.
Read more →-BCTXL
Apr 17, 2023BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR 15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longe
BriaCell Therapeutics Corp. presented promising clinical data at the 2023 AACR Annual Meeting, demonstrating the survival benefits of its Bria-IMT combination treatment in advanced metastatic breast cancer. Out of the 18 patients recruited since the study's reopening in 2021, 15 remain alive, reflecting a noteworthy survival rate. The treatment has not only activated immune responses in patients with weak immune systems but has also shown longer-than-expected survival times compared to previous therapies. This regimen is particularly vital for patients who have limited options due to prior treatment failures.
Read more →-BCTXL
Mar 31, 2023BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created "SpinCo" Entity whereby Shareholders to Receive One New Share of "SpinCo" in Addition to Each Current Share of BriaCell Already He
BriaCell Therapeutics Corp. has announced plans to spin out certain pre-clinical assets into a new entity called SpinCo. Shareholders will receive one share of SpinCo for each share of BriaCell they hold. The spin-out aims to accelerate the development of targeted cancer therapies and provide independent value for the assets. After the transaction, it is anticipated that BriaCell will retain a majority ownership of SpinCo, which will allow both entities to focus on their respective missions.
Read more →-BCTXL
Feb 23, 2023BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer 9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits. Remains well tolerated with no dose limiting toxicitie
BriaCell Therapeutics Corp. has reported promising survival data from their Phase II clinical trial for advanced metastatic breast cancer. Following treatment, 9 out of 11 patients from the previously dosed group remain alive, which the company cites as strong evidence of survival benefits. The regimen, which combines Bria-IMT with Incyte's retifanlimab, is well tolerated, with no adverse dose limiting toxicities observed. Furthermore, 64% of participants demonstrated either disease control or progression-free survival, indicating potential clinical effectiveness within this challenging patient population.
Read more →-BCTXL
Feb 9, 2023BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has reported the results of its annual general and special shareholder meeting held on February 9, 2023. At the meeting, shareholders voted in favor of all proposed resolutions, including the appointment of auditors and election of directors. Additionally, they approved a new omnibus equity incentive plan, which still requires final approval from the Toronto Stock Exchange. The participation rate was noted at 42.94% of issued shares, indicating a strong interest among shareholders.
Read more →-BCTXL
Jan 24, 2023BriaCell CEO Letter to Shareholders Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Succe
BriaCell Therapeutics Corp. has received positive feedback from the FDA on its pivotal study for the lead clinical candidate, Bria-IMT, in combination with a checkpoint inhibitor for advanced metastatic breast cancer. This feedback indicates the potential for a quicker path to commercialization, with a Biologics License Application anticipated following the study's success. The company also announced plans for its new Bria-OTS personalized treatment program, which aims to match cell therapies to patients' HLA types. BriaCell is on track to begin patient dosing as early as the second quarter of 2023, aided by a robust cash position.
Read more →-BCTXL
Jan 23, 2023BriaCell to Investigate Alleged Illegal Trading of Public Securities PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Therapeutics Corp. has announced measures to investigate alleged illegal trading activities affecting its publicly traded securities. The company suspects that certain individuals or entities may have engaged in manipulative practices that could have artificially depressed their share price. To counter this, BriaCell is considering implementing a plan that may involve legal action. The move is intended to protect the interests of shareholders and maintain focus on developing its targeted immunotherapies for cancer patients.
Read more →-BCTXL
Jan 18, 2023BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer BriaCell has received agreement and positive feedback from its End of Phase II meeting with t
BriaCell Therapeutics announced that it has received positive feedback from the FDA during its End of Phase II meeting for its lead candidate, Bria-IMT, in combination with a checkpoint inhibitor for advanced metastatic breast cancer. The FDA has agreed on critical aspects of the upcoming pivotal registration study, including the primary endpoint and patient selection. Successful study results could pave the way for a Biologics License Application (BLA) submission, allowing for commercialization in a treatment area with limited options. This development advances BriaCell's goals in the immuno-oncology sector.
Read more →-BCTXL
Jan 10, 2023BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment BriaCell's new patent protects its novel personalized off-the-shelf cell-based technology for breast
BriaCell Therapeutics Corp. announced the issuance of a new patent for its personalized off-the-shelf cell-based immunotherapy, providing protection until 2040. The company plans to initiate its Bria-OTS clinical study under an Investigational New Drug Application in the first half of 2023, adhering to FDA guidelines. Additionally, two new clinical sites have been added to the Phase II Bria-IMT study to enhance patient access for advanced breast cancer treatments.
Read more →-BCTXL
Dec 8, 2022BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium Positive clinical data reported includes tumor shrinkage, disease control, pr
Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium Positive clinical data reported includes tumor shrinkage, disease control, progression free survival, and potential long term survival benefit i
Read more →-BCTXL
Nov 30, 2022IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies VICTORIA, VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA
Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA, PA, November 30, 2022 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA),
Read more →-BCTXL
Nov 10, 2022BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment at SITC Annual Meeting Bria-IMT regimen in combination with Incyte's retifanlimab produced evidence of disease control, tumor sh
Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment at SITC Annual Meeting Bria-IMT regimen in combination with Incyte's retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell's recent 1
Read more →-BCTXL
Oct 28, 2022BriaCell Therapeutics Corp CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of
CONSOLIDATED FINANCIAL STATEMENTS in United States Dollars of July 31, 2022, BriaCell Therapeutics Corp. (the "Company") determined that it no longer qualified as a "foreign private issuer" as such term is defined in Rule 405 under the Securities Act. This means that, as of A
Read more →-BCTXL
Oct 21, 2022BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing BriaCell has successfully completed its Phase I safety and tole
Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT in combination with Incyte's retifanlimab in advanced breast cance
Read more →-BCTXL
Sep 14, 2022BriaCell Partners with Caris Life Sciences to Expand Patient Outreach and Molecular Profiling PHILADELPHIA, PA and VANCOUVER, British Columbia
BriaCell Partners with Caris Life Sciences Outreach and Molecular Profiling PHILADELPHIA, PA and VANCOUVER, British Columbia, September 14, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
Read more →-BCTXL
Aug 4, 2022BriaCell Secures License for a Promising Novel Anti-Cancer Agent PHILADELPHIA, PA and VANCOUVER, British Columbia
Secures License for a Promising Novel Anti-Cancer Agent PA and VANCOUVER, British Columbia, August 4, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapie
Read more →-BCTXL
Jul 5, 2022BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, le
Partners with Waisman Biomanufacturing Manufacture and Supply Prostate Cancer Immunotherapy Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell's prostate cancer program based on
Read more →-BCTXL
Jun 29, 2022BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment PHILADELPHIA, PA and VANCOUVER, British Columbia
Enters Research Agreement to Identify Novel Targets for Cancer Treatment PA and VANCOUVER, British Columbia, June 29, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targete
Read more →-BCTXL
Jun 24, 2022BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT , in advanced breast cancer patients was published in a leading peer-reviewed
Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT , in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT , through a novel mechanism of action, rapi
Read more →-BCTXL
Jun 13, 2022Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended
BRIACELL THERAPEUTICS CORP. ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfSharebasedPaymentsMember ifrs-full:WarrantReserveMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember ifrs-full:RetainedEarningsMember ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfShareb
Read more →-BCTXL
May 18, 2022BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment PHILADELPHIA, PA and VANCOUVER, British Columbia
Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment PA and VANCOUVER, British Columbia, May 18, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializin
Read more →-BCTXL
Apr 13, 2022BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT , for the treatment of metas
Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT , for the treatment of metastatic breast cancer. Fast Track improves the speed and frequency o
Read more →-BCTXL
Apr 12, 2022BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022 Based on clinical data with Bria-IMT , BriaCell has developed Bria-OTS , an
Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting Based on clinical data with Bria-IMT , BriaCell has developed Bria-OTS , an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy. Bria
Read more →-BCTXL
Apr 7, 2022BriaCell advances preparatory work for new Bria-OTS breast cancer clinical trial Bria-OTS TM would build on BriaCell's existing clinical trial data with Bria-IMT , treating each patient with the optimized pre-manufacture
advances preparatory work for new Bria-OTS breast cancer clinical trial Bria-OTS TM would build on BriaCell's existing clinical trial data with Bria-IMT , treating each patient with the optimized pre-manufactured Bria-OTS formulation based on HLA-type. BriaCell and National Ca
Read more →-BCTXL
Mar 15, 2022Condensed Interim Consolidated Financial Statements For the Three and Six Months Ended
BRIACELL THERAPEUTICS CORP. ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfSharebasedPaymentsMember ifrs-full:WarrantReserveMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember ifrs-full:RetainedEarningsMember ifrs-full:IssuedCapitalMember ifrs-full:ReserveOfShareb
Read more →-BCTXL
Feb 28, 2022BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment PHILADELPHIA, PA and VANCOUVER, British Columbia
Adds Two Clinical Trial Sites to Accelerate Patient Enrollment PA and VANCOUVER, British Columbia, February 28, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immu
Read more →-BCTXL
Feb 23, 2022BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board PHILADELPHIA, PA and VANCOUVER, British Columbia
Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board PA and VANCOUVER, British Columbia, February 23, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company special
Read more →-BCTXL
Feb 16, 2022BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer PHILADELPHIA, PA and VANCOUVER, British Columbia
Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer PA and VANCOUVER, British Columbia, February 16, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company special
Read more →-BCTXL
Feb 10, 2022BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program
to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased sinc
Read more →-BCTXL
Jan 19, 2022BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders NEW YORK and VANCOUVER, British Columbia
Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders YORK and VANCOUVER, British Columbia, January 19, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), is pleased to announce that all resolution
Read more →-BCTXL
Jan 5, 2022BRIACELL THERAPEUTICS CORP. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING AND MANAGEMENT INFORMATION CIRCULAR WITH RESPECT TO THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF BRIACELL THERAPEUTICS CORP. TO BE HEL
OF ANNUAL GENERAL AND SPECIAL MEETING INFORMATION CIRCULAR ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF BRIACELL THERAPEUTICS CORP. BE HELD ON JANUARY 18, 2022 300 - 235 15th Street West Vancouver, BC V7T 2X1 OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Read more →-BCTXL
Dec 29, 2021BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under BCT'; Remains BCTX' on Nasdaq BERKELEY, Calif. and VANCOUVER, British Columbia
to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under BCT'; Remains BCTX' on Nasdaq Calif. and VANCOUVER, British Columbia, December 29, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stag
Read more →-BCTXL
Dec 17, 2021BriaCell Announces Insiders' Intention to Purchase up to 10% of Public Market Securities Insiders intend to acquire up to approximately 10% of BriaCell's basic common shares, or 1.59 million shares Corporate buyback prog
Announces Insiders' Intention to Purchase up to 10% of Public Market Securities Insiders intend to acquire up to approximately 10% of BriaCell's basic common shares, or 1.59 million shares Corporate buyback program will continue; 501,703 shares and 143,236 warrants repurchas
Read more →-BCTXL
Dec 15, 2021Condensed Interim Consolidated Financial Statements For the Three Months Ended
Condensed Interim Consolidated Financial Statements For the Three Months Ended October Expressed in United States BriaCell Therapeutics Corp Unaudited Condensed Interim Consolidated Statements of Financial Position As of October 31, 2021 and July 31, 2021 (Expressed in US
Read more →-BCTXL
Dec 9, 2021BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium NEW YORK and VANCOUVER, British Columbia
Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium YORK and VANCOUVER, British Columbia, December 9, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
Read more →-BCTXL
Nov 18, 2021BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study NEW YORK and VANCOUVER, British Columbia
Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study YORK and VANCOUVER, British Columbia, November 18, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biot
Read more →-BCTXL
Nov 12, 2021BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences Calif. and VANCOUVER, British Columbia, November 12, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage
Read more →-BCTXL
Nov 5, 2021BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board NEW YORK and VANCOUVER, British Columbia
Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board YORK and VANCOUVER, British Columbia, November 5, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"),
Read more →-BCTXL
Nov 2, 2021BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors NEW YORK and VANCOUVER, British Columbia
Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors YORK and VANCOUVER, British Columbia, November 2, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company speci
Read more →-BCTXL
Oct 29, 2021Consolidated Financial Statements For the Years Ended
Financial Statements the Years Ended July 31, 2021 and 2020 in United States Dollars OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM the Board of Directors and Shareholders of BriaCell Therapeutics Corp. on the Consolidated Financial Statements have audited the accompanyin
Read more →-BCTXL
Oct 5, 2021October is Breast Cancer Awareness Month - BriaCell is Advancing the Fight with its Immunotherapy BERKELEY, Calif. and VANCOUVER, British Columbia
October is Breast Cancer Awareness Month - BriaCell is Advancing the Fight with its Immunotherapy BERKELEY, Calif. and VANCOUVER, British Columbia, October 5, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage
Read more →-BCTXL
Sep 22, 2021BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid BERKELEY, Calif. and VANCOUVER, British Columbia
Announces TSXV Acceptance of Normal Course Issuer Bid Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in t
Read more →-BCTXL
Sep 9, 2021BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants Calif. and VANCOUVER, British Columbia, September 9, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage biotec
Read more →-BCTXL
Sep 1, 2021BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors BERKELEY, Calif. and VANCOUVER, British Columbia
Therapeutics Appoints Marc Lustig to its Board of Directors Calif. and VANCOUVER, British Columbia, September 1, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted i
Read more →-BCTXL
Aug 23, 2021BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 NEW YORK and VANCOUVER, British Columbia
to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 YORK and VANCOUVER, British Columbia, Aug. 23, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology
Read more →-BCTXL
Aug 19, 2021BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-at
and ImaginAb Announce Collaboration to Evaluate Imaging Technology in Advanced Breast to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021-BriaCell
Read more →-BCTXL
Jul 14, 2021BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment NEW YORK and VANCOUVER, British Columbia
Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment YORK and VANCOUVER, British Columbia, July 14, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology c
Read more →-BCTXL
Jul 12, 2021BriaCell to Present at Three Upcoming Investor Conferences BERKELEY, Calif. and VANCOUVER, British Columbia
to Present at Three Upcoming Investor Conferences Calif. and VANCOUVER, British Columbia, July 12, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies
Read more →-BCTXL
Jun 16, 2021BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and n
Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. Bria-OTS , an off-the-shelf personali
Read more →-BCTXL
Jun 10, 2021BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes BERKELEY, Calif. and
BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes Calif. and VANCOUVER, British Columbia, June 10, 2021- BriaCell Therapeutics
Read more →-BCTXL
Jun 9, 2021BriaCell to Hold Corporate and Clinical Update Conference Call Wednesday
to Hold Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET Calif. and VANCOUVER, British Columbia, June 9, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology comp
Read more →-BCTXL
Jun 7, 2021BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement Berkeley, Calif. And Vancouver, British Columbia
Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement Calif. And Vancouver, British Columbia, June 07, 2021 - (GLOBE NEWSWIRE) BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or "BriaCell"), a clinical-stage biotechnology company
Read more →-BCTXL
Jun 3, 2021BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement Berkeley, Calif. And VANCOUVER, British Columbia
Therapeutics Corp. Announces US$27.2 Million Private Placement Calif. And VANCOUVER, British Columbia, June 03, 2021 - (GLOBE NEWSWIRE) BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or "BriaCell"), a clinical-stage biotechnology company specializin
Read more →-BCTXL
Jun 2, 2021BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of Eye-Bulging' Tumo r 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches
Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of Eye-Bulging' Tumor 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors (1) Top Responde
Read more →-BCTXL
May 19, 2021BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING BERKELEY, Calif., and VANCOUVER, British Columbia
THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING Calif., and VANCOUVER, British Columbia, May 19, 2021 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immun
Read more →-BCTXL
May 11, 2021BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director BERKELEY, Calif. and VANCOUVER, British Columbia
to Participate at Upcoming Conferences and Appoints Senior R&D Director Calif. and VANCOUVER, British Columbia, May 11, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targ
Read more →-BCTXL
Apr 15, 2021BriaCell Announces Investor and Media Outreach Programs BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Investor and Media Outreach Programs Calif. and VANCOUVER, British Columbia, April 15, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies f
Read more →-BCTXL
Apr 12, 2021BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCe
Read more →-BCTXL
Mar 30, 2021BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021 Clinical and pathological findings from clinical trial of the Bria-IMT regimen alone and in combination with immune che
Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021 Clinical and pathological findings from clinical trial of the Bria-IMT regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at t
Read more →-BCTXL
Feb 23, 2021BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing BERKELEY, Calif. and VANCOUVER, British Columbia
Announces Pricing of US$25 Million Public Offering and Nasdaq Listing Calif. and VANCOUVER, British Columbia, February 23, 2021- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in t
Read more →Competitive Position
How BCTXL ranks across every disease it competes inCompetitive Position is a premium feature
See how BCTXL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial